Skip to content

Regenicin, Inc.: 10-Q filed 2014-05-20

What Regenicin, Inc. reported in its quarterly report filed 2014-05-20 (fiscal Q2 2014): 19 published measures, 51 facts as tagged in accession 0001255294-14-000467.

This filing

Form
10-Q (quarterly report)
Filed
2014-05-20
Fiscal period
fiscal Q2 2014
Accession
0001255294-14-000467 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Regenicin, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-3140,892USD
At 2013-09-3096,335USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-314,192,825USD
At 2013-09-304,236,073USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-31-4,151,933USD
At 2013-09-30-4,139,738USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2014-03-31-118,825USD182
2007-09-06 to 2014-03-31-4,042,565USD2399
2012-10-01 to 2013-03-31-252,670USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2014-03-3199,564USD182
2007-09-06 to 2014-03-317,053,304USD2399
2012-10-01 to 2013-03-31243,083USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2007-09-06 to 2014-03-31-3,007,500USD2399

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-03-31-13,483,470USD
At 2013-09-30-13,092,713USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
2013-10-01 to 2014-03-3127,556USD182
2007-09-06 to 2014-03-311,276,193USD2399

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-288,230USD90
2013-10-01 to 2014-03-31-487,500USD182
2007-09-06 to 2014-03-31-11,622,464USD2399
2013-01-01 to 2013-03-31-176,613USD90
2012-10-01 to 2013-03-31-483,839USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-3133,392USD
At 2013-09-3088,835USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-314,192,825USD
At 2013-09-304,236,073USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-311,511,988USD
At 2013-09-301,392,481USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-01-01 to 2014-03-31288,230USD90
2013-10-01 to 2014-03-31487,500USD182
2007-09-06 to 2014-03-3111,622,464USD2399
2013-01-01 to 2013-03-31176,613USD90
2012-10-01 to 2013-03-31483,839USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2007-09-06 to 2014-03-311,563,719USD2399

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-31125,844,181shares
At 2013-09-30115,730,649shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-03-318,854,244USD
At 2013-09-308,501,390USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-03-3130,153USD
At 2013-09-3066,335USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-343,268USD90
2013-10-01 to 2014-03-31-390,757USD182
2007-09-06 to 2014-03-31-13,483,470USD2399
2013-01-01 to 2013-03-31-286,139USD90
2012-10-01 to 2013-03-31-843,204USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31288,230USD90
2013-10-01 to 2014-03-31459,944USD182
2007-09-06 to 2014-03-315,782,552USD2399
2013-01-01 to 2013-03-31176,613USD90
2012-10-01 to 2013-03-31483,839USD182

Inspect the source

Entity
Regenicin, Inc. / CIK 0001412659
Captured
SEC response SHA-256
66d33e554adc1e643294d5e778c52aa5121a74d07c71bf640453c952267c0d14

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001412659.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))